AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.
“This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,” said Ceram CEO, Tony Kinsella.
Controlled Release Technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.
With Healthcare as one of its largest markets, the materials development business has ambitious plans to continue its growth in the US and Europe.
Tony Kinsella continued: “Our work is focussed on commercial development of materials for industrial applications – exactly what a recent news item on the BBC said was lacking in Britain. We have, for example, recently helped Greatbatch Medical to gain FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste – a product that has seen substantial annual growth over the last decade, creating significant incomes for both GSK and the UK.”
Ceram is an independent, international materials technology company that focuses on innovation, sustainability and quality assurance of materials.
Headquartered in Staffordshire, UK, and with approved laboratories around the world, Ceram solves product and process challenges across a range of materials to help clients improve performance, comply with regulations and develop their sustainability performance in order to gain a competitive advantage and increase profitability.
Ceram operates in a wide variety of sectors around the world.
For more information visit www.ceram.com/crt